- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06347627
Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18
Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18: a Mixed-methods Assessment of Acceptance of HPV Vaccine With Experiments on Communication Strategies
Study Overview
Status
Conditions
Intervention / Treatment
- Behavioral: Group 1 (I x S x S x F)
- Behavioral: Group 2 (O x S x S x F)
- Behavioral: Group 3 (I x E x S x F)
- Behavioral: Group 4 (O x E x S x F)
- Behavioral: Group 5 (I x S x S x M)
- Behavioral: Group 6 (O x S x S x M)
- Behavioral: Group 7 (I x E x S x M)
- Behavioral: Group 8 (O x E x S x M)
- Behavioral: Group 9 (I x S x D x F)
- Behavioral: Group 10 (O x S x D x F)
- Behavioral: Group 11 (I x E x D x F)
- Behavioral: Group 12 (O x E x D x F)
- Behavioral: Group 13 (I x S x D x M)
- Behavioral: Group 14 (O x S x D x M)
- Behavioral: Group 15 (I x E x D x M)
- Behavioral: Group 16 (O x E x D x M)
Detailed Description
This study will implement an experiment as a sixteen-arm randomized controlled trial in an online survey environment. Before the experiment, participants, who are Japanese caregivers with daughters aged 12-18 who have not received an HPV vaccine, will first answer a pre-experiment survey. The survey will collect information on participants' socio-demographic data and key decision-making factors for HPV vaccine acceptance and confidence. Then, the study will randomly assign the participants to view one digital communication message using a 2 × 2 × 2 × 2 between-person factorial experiment on 'components of message.' The sixteen experimental messages will be developed based on real social media messages posted between November 2021 and April 2022, when the Japanese government prepared to reinstate an active recommendation of HPV vaccines for eligible girls after eight and a half years of suspension.
The sixteen messages will assess four factors: messenger, style, content, and misinformation. Each message will be similar except for one variable in consideration. The messenger component will be whether the message is from an individual or an organization. As individual messengers, the study will set a fictional male or female with common Japanese names who actively communicate about HPV vaccines. As organizational messengers, the study will use the existing accounts of the Ministry of Health, Labour and Welfare or the Japan Cancer Society or a fictional account of an anti-vaccine group. The style component will be whether the message conveys information through storytelling or scientific data. Messages will include personal stories for the storytelling style and statistics for the scientific data style. The content component will be whether the message conveys information about the effectiveness of the HPV vaccine in preventing diseases or the safety of the HPV vaccine. The contents will be built on both factual information and misconceptions about HPV vaccine safety and effectiveness that are often mentioned in the actual social media posts. The misinformation component will be whether the message conveys misinformation or factual information. The study will debrief all respondents exposed to misinformation after the survey.
Lastly, the study will collect data as a post-experiment survey to evaluate how an online message influenced caregivers' trust, confidence, and motivation to vaccinate.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- London School of Hygiene and Tropical Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female adult caregivers, older than 20, with daughters aged 12-18 who have received none or only one shot of HPV vaccine.
Exclusion Criteria:
- Caregivers who do not agree to participate in survey, experiment, or both.
- Caregivers with daughters who have already received two or more HPV vaccines.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (I x S x S x F)
Participants in Group 1 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Safety x Storytelling x Factual
|
Experimental: Group 2 (O x S x S x F)
Participants in Group 2 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Safety x Storytelling x Factual
|
Experimental: Group 3 (I x E x S x F)
Participants in Group 3 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Effectiveness x Storytelling x Factual
|
Experimental: Group 4 (O x E x S x F)
Participants in Group 4 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Effectiveness x Storytelling x Factual
|
Experimental: Group 5 (I x S x S x M)
Participants in Group 5 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Safety x Storytelling x Misinformation
|
Experimental: Group 6 (O x S x S x M)
Participants in Group 6 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Safety x Storytelling x Misinformation
|
Experimental: Group 7 (I x E x S x M)
Participants in Group 7 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Effectiveness x Storytelling x Misinformation
|
Experimental: Group 8 (O x E x S x M)
Participants in Group 8 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Effectiveness x Storytelling x Misinformation
|
Experimental: Group 9 (I x S x D x F)
Participants in Group 9 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Safety x Scientific data x Factual
|
Experimental: Group 10 (O x S x D x F)
Participants in Group 10 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Safety x Scientific data x Factual
|
Experimental: Group 11 (I x E x D x F)
Participants in Group 11 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Effectiveness x Scientific data x Factual
|
Experimental: Group 12 (O x E x D x F)
Participants in Group 12 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Factual" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Effectiveness x Scientific data x Factual
|
Experimental: Group 13 (I x S x D x M)
Participants in Group 13 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Safety x Scientific data x Misinformation
|
Experimental: Group 14 (O x S x D x M)
Participants in Group 14 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Safety x Scientific data x Misinformation
|
Experimental: Group 15 (I x E x D x M)
Participants in Group 15 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Individual x Effectiveness x Scientific data x Misinformation
|
Experimental: Group 16 (O x E x D x M)
Participants in Group 16 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Misinformation" factors.
The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.
|
Experimental message: Organization x Effectiveness x Scientific data x Misinformation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Willingness to receive HPV vaccines for daughters
Time Frame: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
|
A degree of a change in willingness to receive HPV vaccines after viewing an experimental message will be scored on a 5-point scale.
The options are 1) much less willing to get the HPV vaccine for my daughter, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.
|
This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confidence in HPV vaccine safety
Time Frame: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
|
A degree of a change in confidence regarding HPV vaccine safety after viewing an experimental message will be scored on a 5-point scale.
The options are 1) much less confident that the HPV vaccine is safe, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.
|
This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leesa Lin, PhD, London School of Hygiene and Tropical Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- UW23139
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Lancaster UniversityRecruiting
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Group 1 (I x S x S x F)
-
TaiHao Medical Inc.Columbia University; Virginia Polytechnic Institute and State University; Taipei...CompletedBreast Cancer | Breast DiseasesUnited States
-
Human Genome Sciences Inc.GlaxoSmithKlineCompleted
-
University of OxfordNational Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...CompletedPlasmodium Falciparum MalariaUnited Kingdom
-
Jas ChahalCompleted
-
University of OxfordCompleted
-
MeiraGTx UK II LtdCompletedHead and Neck Cancer | Radiation-Induced Parotid Gland Hypofunction | Xerostomia Due to RadiotherapyUnited States, Canada
-
MaterialiseTerminated
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
Weill Medical College of Cornell UniversityActive, not recruitingMalignant Neoplasm of Breast Stage IUnited States